Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring

Pathology Research and Practice

Volumn 206, Issue 9, 2010, Pages 642-646

  Torres, Thiago da Silva ^a   Aguila, Marcia Barbosa ^a   Mandarim de Lacerda, Carlos Alberto ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cardiac remodeling; Hypertension; Low protein diet; Rosiglitazone

Indexed keywords

GLUCOSE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; GESTATION PERIOD; GLUCOSE BLOOD LEVEL; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; MALE; MATERNAL NUTRITION; MORNING DOSAGE; NONHUMAN; PROGENY; PROTEIN INTAKE; PROTEIN RESTRICTION; RAT; VASCULARIZATION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIET, PROTEIN-RESTRICTED; FIBROSIS; HEART; HYPOGLYCEMIC AGENTS; MALE; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; VENTRICULAR REMODELING;

EID: 77956249704     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.03.007     Document Type: Article

References (38)

1. Almeida J.R., Mandarim-de-Lacerda C.A. Overweight is gender-dependent in prenatal protein - calorie restricted adult rats acting on the blood pressure and the adverse cardiac remodeling. Life Sci. 2005, 77:1307-1318.
2. Barker D.J., Fall C.H. Fetal and infant origins of cardiovascular disease. Arch. Dis. Child 1993, 68:797-799.
3. Bezerra D.G., Andrade L.M.L., Cruz F.O.P., Mandarim-de-Lacerda C.A. Atorvastatin attenuates cardiomyocyte loss in adult rats from protein-restricted dams. J. Card Fail 2008, 14:151-160.
4. Brawley L., Itoh S., Torrens C., Barker A., Bertram C., Poston L., et al. Dietary protein restriction in pregnancy induces hypertension and vascular defects in rat male offspring. Pediatr. Res. 2003, 54:83-90.
5. Calnek D.S., Mazzella L., Roser S., Roman J., Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscl. Thromb. Vasc. Biol. 2003, 23:52-57.
6. Chen K., Chen J., Li D., Zhang X., Mehta J.L. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 2004, 44:655-661.
7. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68:879-887.
8. Duarte-Silva P., Stam A. Discriminant analysis. Reading and Understanding Multivariate Statistics 1998, 277-318. American Psychological Association, Washington, DC. L.G. Grimm, P.R. Yarnold (Eds.).
9. Duda D.G., Fukumura D., Jain R.K. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol. Med. 2004, 10:143-145.
10. Engel F.B. Cardiomyocyte proliferation: a platform for mammalian cardiac repair. Cell Cycle 2005, 4:1360-1363.
11. Franco C.M., Arruda R.M., Dantas A.P., Kawamoto E.M., Fortes Z.B., Scavone C., et al. Intrauterine undernutrition: expression and activity of the endothelial nitric oxide synthase in male and female adult offspring. Cardiovasc. Res. 2002, 56:145-153.
12. Geng D.F., Wu W., Jin D.M., Wang J.F., Wu Y.M. Effect of peroxisome proliferator-activated receptor gamma ligand, Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int. J. Cardiol. 2006, 113:86-91.
13. Gonon A.T., Bulhak A., Labruto F., Sjoquist P.O., Pernow J. Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res. Cardiol. 2007, 102:80-89.
14. Grommes C., Landreth G.E., Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004, 5:419-429.
15. Hao G.H., Niu X.L., Gao D.F., Wei J., Wang N.P. Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Brit. J. Pharmacol. 2008, 153:1409-1419.
16. Hocher B. Fetal programming of cardiovascular diseases in later life - mechanisms beyond maternal undernutrition. J. Physiol. 2007, 579:287-288.
17. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. NEJM 2007, 357:28-38.
18. Iglarz M., Touyz R.M., Viel E.C., Paradis P., Amiri F., Diep Q.N., et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003, 42:737-743.
19. Kawamura M., Itoh H., Yura S., Mogami H., Suga S., Makino H., et al. Undernutrition in utero augments systolic blood pressure and cardiac remodeling in adult mouse offspring: possible involvement of local cardiac angiotensin system in developmental origins of cardiovascular disease. Endocrinology 2007, 148:1218-1225.
20. Krall R.L. Cardiovascular safety of rosiglitazone. Lancet 2007, 369:1995-1996.
21. Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 2005, 123:993-999.
22. Liu H.R., Tao L., Gao E., Lopez B.L., Christopher T.A., Willette R.N., et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc. Res. 2004, 62:135-144.
23. Mandarim-de-Lacerda C.A. Stereological tools in biomedical research. Ann. Braz. Acad. Sci. 2003, 75:469-486.
24. Molavi B., Chen J., Mehta J.L. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Amer. J. Physiol. 2006, 291:H687-H693.
25. Moreau P., d'Uscio L.V., Shaw S., Takase H., Barton M., Luscher T.F. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997, 96:1593-1597.
26. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. NEJM 2007, 356:2457-2471.
27. Pinheiro A.R., Salvucci I.D., Aguila M.B., Mandarim-de-Lacerda C.A. Protein restriction during gestation and/or lactation causes adverse transgenerational effects on biometry and glucose metabolism in F1 and F2 progenies of rats. Clin. Sci. (Lond.) 2008, 114:381-392.
28. Quinn R. Comparing rat's to human's age: how old is my rat in people years?. Nutrition 2005, 21:775-777.
29. Reeves P.G., Nielsen F.H., Fahey G.C. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr. 1993, 123:1939-1951.
30. Torres T.S., Silva G.D., Aguila M.B., de Carvalho J.J., Mandarim-de-Lacerda C.A. Effects of rosiglitazone (a peroxysome proliferator-activated receptor gamma agonist) on the blood pressure and aortic structure in metabolically programmed (perinatal low protein) rats. Hypertens. Res. 2008, 31:965-975.
31. Wainwright P.E. Issues of design and analysis relating to the use of multiparous species in developmental nutritional studies. J. Nutr. 1998, 128:661-663.
32. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002, 16:1027-1040.
33. Weber K.T. Cardioreparation in hypertensive heart disease. Hypertension 2001, 38:588-591.
34. Weber K.T., Sun Y., Diez J. Fibrosis: a living tissue and the infarcted heart. J. Am. Coll. Cardiol. 2008, 52:2029-2031.
35. Woods L.L., Ingelfinger J.R., Nyengaard J.R., Rasch R. Maternal protein restriction suppresses the newborn renin-angiotensin system and programs adult hypertension in rats. Pediatr. Res. 2001, 49:460-467.
36. Wu L., Wang R., De Champlain J., Wilson T.W. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am. J. Hypertens. 2004, 17:749-756.
37. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2000, 271:571-574.
38. Yue T.L., Bao W., Gu J.L., Cui J., Tao L., Ma X.L., et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.